Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H22FNO.ClH |
Molecular Weight | 299.811 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
InChI
InChIKey=MQHYXXIJLKFQGY-UHFFFAOYSA-N
InChI=1S/C16H22FNO.ClH/c1-13-8-11-18(12-9-13)10-2-3-16(19)14-4-6-15(17)7-5-14;/h4-7,13H,2-3,8-12H2,1H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H22FNO |
Molecular Weight | 263.3504 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CNS Activity
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MELPERON Approved UseMelperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients. |
|||
Primary | MELPERON Approved UseMelperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients. |
|||
Primary | MELPERON Approved UseMelperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients. |
PubMed
Title | Date | PubMed |
---|---|---|
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. | 2001 Oct |
|
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. | 2002 Nov 29 |
|
Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. | 2003 Jan |
|
The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia. | 2003 Jan 1 |
|
A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia. | 2003 Jul 1 |
|
Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. | 2003 Mar |
|
P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6. | 2004 Dec |
|
[The case of a 86-years old woman first diagnosed with Huntington's disease]. | 2004 Nov |
|
Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor. | 2005 Feb |
|
Antipsychotic drugs and QT prolongation. | 2005 Sep |
|
Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone. | 2006 Apr |
|
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). | 2008 Dec 22 |
|
Antipsychotics and risk of venous thromboembolism: A population-based case-control study. | 2009 Aug 9 |
|
Acute administration of clozapine and risperidone altered dopamine metabolism more in rat caudate than in nucleus accumbens: a dose-response relationship. | 2010 Apr-Jun |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. | 2010 Feb |
|
Four-digit replantation in a mentally retarded person: a case report. | 2010 Sep 30 |
Patents
Sample Use Guides
The recommended dose of melperone (in form of hydrochloride salt) is 25-75 mg/day. In the case of restless and confused patients the drug is given at a dose of 50-100 mg at the beginning of the treatment. The dose can be increased up to 200 mg if necessary. In severe disorders of confusion and confusion with aggression and hallucinatory conditions, the daily dose can be increased to up to 400 mg melperone HCl.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:25:35 UTC 2023
by
admin
on
Fri Dec 15 15:25:35 UTC 2023
|
Record UNII |
88G640374K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
289623
Created by
admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
|
PRIMARY | RxNorm | ||
|
m7165
Created by
admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
|
PRIMARY | Merck Index | ||
|
C008522
Created by
admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
|
PRIMARY | |||
|
760102
Created by
admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
|
PRIMARY | |||
|
SUB14503MIG
Created by
admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
|
PRIMARY | |||
|
15386
Created by
admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
|
PRIMARY | |||
|
216-599-9
Created by
admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
|
PRIMARY | |||
|
88G640374K
Created by
admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
|
PRIMARY | |||
|
DTXSID10936649
Created by
admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
|
PRIMARY | |||
|
1622-79-3
Created by
admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
|
PRIMARY | |||
|
100000092068
Created by
admin on Fri Dec 15 15:25:35 UTC 2023 , Edited by admin on Fri Dec 15 15:25:35 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |